[go: up one dir, main page]

PT2411397E - Derivados de isotiazolo-pirimidinadiona como moduladores de trpa1 - Google Patents

Derivados de isotiazolo-pirimidinadiona como moduladores de trpa1

Info

Publication number
PT2411397E
PT2411397E PT107160491T PT10716049T PT2411397E PT 2411397 E PT2411397 E PT 2411397E PT 107160491 T PT107160491 T PT 107160491T PT 10716049 T PT10716049 T PT 10716049T PT 2411397 E PT2411397 E PT 2411397E
Authority
PT
Portugal
Prior art keywords
isothiazolo
pyrimidinedione derivatives
trpa1 modulators
trpa1
modulators
Prior art date
Application number
PT107160491T
Other languages
English (en)
Inventor
Sukeerthi Kumar
Abraham Thomas
Sanjay Margal
Neelima Khairatkar-Joshi
Indranil Mukhopadhyay
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of PT2411397E publication Critical patent/PT2411397E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PT107160491T 2009-03-23 2010-03-22 Derivados de isotiazolo-pirimidinadiona como moduladores de trpa1 PT2411397E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21

Publications (1)

Publication Number Publication Date
PT2411397E true PT2411397E (pt) 2013-06-06

Family

ID=42236291

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107160491T PT2411397E (pt) 2009-03-23 2010-03-22 Derivados de isotiazolo-pirimidinadiona como moduladores de trpa1

Country Status (22)

Country Link
US (1) US8575178B2 (pt)
EP (1) EP2411397B1 (pt)
JP (1) JP2012521405A (pt)
KR (1) KR20120001746A (pt)
CN (1) CN102395592A (pt)
AP (1) AP2011005888A0 (pt)
AU (1) AU2010227224A1 (pt)
BR (1) BRPI1009372A2 (pt)
CA (1) CA2756534A1 (pt)
DK (1) DK2411397T3 (pt)
EA (1) EA201190191A1 (pt)
ES (1) ES2424340T3 (pt)
IL (1) IL215179A0 (pt)
MX (1) MX2011009821A (pt)
PE (1) PE20120764A1 (pt)
PL (1) PL2411397T3 (pt)
PT (1) PT2411397E (pt)
SG (2) SG174403A1 (pt)
SI (1) SI2411397T1 (pt)
UA (1) UA107342C2 (pt)
WO (1) WO2010109328A1 (pt)
ZA (1) ZA201107646B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2411393B1 (en) 2009-03-23 2014-01-22 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as trpa1 modulators
CA2756535A1 (en) 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as trpa1 modulators
EP2655377B1 (en) 2010-12-20 2016-03-30 Glenmark Pharmaceuticals S.A. 2-amino-4-arylthiazole compounds as trpa1 antagonists
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
CA2836856A1 (en) * 2011-06-13 2012-12-20 Glenmark Pharmaceuticals, S.A. Treatment of respiratory disorders using trpa1 antagonists
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
BR112013031820A2 (pt) 2011-06-22 2016-12-13 Glenmark Pharmaceutical S A composições farmacêuticas, incluindo para administração oral e por inalação, usos de quantidade sinergicamente eficaz de antagonista trpa1 e métodos para tratar distúrbios respiratórios e para melhorar a função pulmonar
WO2013014597A1 (en) 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
TWI640519B (zh) * 2011-11-29 2018-11-11 泰緯生命科技股份有限公司 Hec1活性調控因子及其調節方法
CA2857109A1 (en) 2011-12-05 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
MX354014B (es) 2012-06-08 2018-02-08 Glenmark Pharmaceuticals Sa Amidas de compuestos de 2-amino-4-ariltiazol y sus sales.
AU2013326429B2 (en) 2012-10-01 2017-10-26 Orion Corporation N-prop-2-ynyl carboxamide derivatives and their use as TRPA1 antagonists
JP2016504988A (ja) 2012-11-14 2016-02-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft イミダゾピリジン誘導体
AU2014282762B2 (en) 2013-06-20 2016-11-10 Ichnos Sciences SA Nanoparticulate formulation comprising a TRPA1 antagonist
RU2016115093A (ru) 2013-10-15 2017-11-21 Гленмарк Фармасьютикалс С.А. Фармацевтическая композиция, содержащая антагонист trpa1 и анальгетический агент
WO2015155306A1 (en) * 2014-04-11 2015-10-15 Almirall, S.A. New trpa1 antagonists
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
WO2018233648A1 (zh) * 2017-06-21 2018-12-27 南京明德新药研发股份有限公司 作为TLR8激动剂的异噻唑并[4,3-d]嘧啶-5,7-二胺衍生物
CN112794860B (zh) * 2021-03-24 2021-06-29 上海肇钰医药科技有限公司 噁唑嘧啶酮酰胺类化合物或其可药用盐,制备方法及用途
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) * 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
WO2004014916A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2004055054A1 (en) 2002-12-18 2004-07-01 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
EP1713815A4 (en) * 2004-02-11 2009-03-11 Smithkline Beecham Corp PTH AGONISTS
WO2005089206A2 (en) 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
WO2006083005A1 (ja) 2005-02-03 2006-08-10 Takeda Pharmaceutical Company Limited 縮合ピリミジン誘導体およびその用途
ES2436225T3 (es) 2005-12-22 2013-12-27 Hydra Biosciences, Inc. Inhibidores TRPA1 para tratamiento del dolor
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
CL2008000252A1 (es) 2007-01-29 2008-03-14 Xenon Pharmaceuticals Inc Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir
EP3663295A1 (en) * 2007-06-22 2020-06-10 Eli Lilly And Co. 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders

Also Published As

Publication number Publication date
ES2424340T3 (es) 2013-10-01
US20120010223A1 (en) 2012-01-12
AU2010227224A1 (en) 2011-09-29
ZA201107646B (en) 2012-06-25
EP2411397B1 (en) 2013-05-29
EP2411397A1 (en) 2012-02-01
IL215179A0 (en) 2011-12-29
SG174403A1 (en) 2011-10-28
KR20120001746A (ko) 2012-01-04
SI2411397T1 (sl) 2013-07-31
PE20120764A1 (es) 2012-06-27
US8575178B2 (en) 2013-11-05
SG184766A1 (en) 2012-10-30
CN102395592A (zh) 2012-03-28
AP2011005888A0 (en) 2011-10-31
JP2012521405A (ja) 2012-09-13
CA2756534A1 (en) 2010-09-30
WO2010109328A1 (en) 2010-09-30
HK1166081A1 (en) 2012-10-19
PL2411397T3 (pl) 2013-10-31
BRPI1009372A2 (pt) 2016-05-31
AU2010227224A2 (en) 2011-10-27
DK2411397T3 (da) 2013-08-05
EA201190191A1 (ru) 2012-11-30
MX2011009821A (es) 2012-01-25
UA107342C2 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
AP2948A (en) Thienopyrmidinedione derivatives as TRPA1 modulators
ZA201107646B (en) Isothiazolo-prrimidinedione derivatives as trpa1 modulators
AP3280A (en) Fused pyrimidine-dione derivatives as TRPA1 modulators
IL219087A0 (en) Benzimidazole-imidazole derivatives
IL217956A0 (en) N1-sulfonyl-5-fluoropyrimidinone derivatives
IL217953A0 (en) 5-fluoropyrimidinone derivatives
IL215169A0 (en) Isoxazole -pyridine derivatives as gaba modulators
IL216007A0 (en) Isoxazole-pyridine derivatives
IL215109A0 (en) Isoxazole-pyridazine derivatives
IL214941A0 (en) Isoxazole-pyrazole derivatives
IL217952A0 (en) N1-acyl-5-fluoropyrimidinone derivatives
IL213927A0 (en) Deoxyactagardine derivatives
IL216761A0 (en) Pyrazinooxazepine derivatives
GB0921967D0 (en) Novel Aryloxyanilide Derivatives
IL213262A0 (en) Tetrahydronaphthalen-2-ol derivatives
GB0912499D0 (en) Indopyl-pyridone derivatives
AP2011005883A0 (en) Furopyrimidinedione derivatives as TRPA1 modulators.